Skip to main content

emaretamig

Generic: Emaretamig

emaretamig: 2 clinical trials tracked.

emaretamig evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about emaretamig, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator's Choice of Adjuvant Chemotherapy in Participants With Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

NCT07024615Registry updated 2026-02-18·Phase 1
Recruiting

Primary endpoint: Number of participants with Adverse Events (AEs)

Interventionalopen25 targetStarted 2025-10Completion 2028-012 sites · United StatesAstellas Pharma Global Development, Inc.

A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination With Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With mFOLFIRINOX in Participants With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

NCT05365581Registry updated 2026-07-15·Phase 1
Recruiting

Primary endpoint: Incidence of Dose Limiting Toxicities (DLTs) (Phase 1 Dose Escalation)

InterventionalRandomizedopen398 targetStarted 2022-06Completion 2028-0546 sites · China, France, Italy, Japan…Astellas Pharma Global Development, Inc.